#USA #New York #Pomerantz LLP #Aquestive Therapeutics #NDA Review

Pomerantz Law Firm Launches Investigation into Aquestive Therapeutics

Pomerantz Law Firm has announced that it is conducting an investigation on behalf of the investors of Aquestive Therapeutics, Inc. (NASDAQ: AQST). This inquiry focuses on potential securities fraud or other unlawful practices by the company and its officers. The call for attention comes in the wake of a recent announcement that raised significant concerns about the company's operations and regulatory compliance.

Background of the Investigation

The firm is reaching out to investors following distressing news reported on January 9, 2026. During this announcement, the President and CEO of Aquestive, gave an update regarding the company’s New Drug Application (NDA) for its product, Anaphylm. The announcement indicated that the FDA had identified deficiencies with the NDA that would prevent discussions regarding labeling and post-marketing commitments. Unfortunately, specifics about these deficiencies were not disclosed, leaving investors anxious over the implications for the company's future.

This development had an immediate impact on the stock price of Aquestive; shares dropped by $2.30, which constitutes a startling 37.04% decline, closing at $3.91 per share on the same day. This dramatic shift raised alarms among investors who are now questioning the integrity and transparency of the company’s leadership.

The Role of Pomerantz LLP

Pomerantz LLP is a recognized name in the legal field, especially for its work in corporate, securities, and antitrust class litigation. The firm, which was founded over 85 years ago by Abraham L. Pomerantz—often called the dean of the class action bar—has a storied history of advocating for investors’ rights throughout cases of securities fraud and corporate misconduct. The firm has recovered substantial damages for victims in the past and is determined to uphold this reputation through their present investigation announcement.

For investors of Aquestive Therapeutics, this is a critical time for engagement. Pomerantz has invited affected investors to make contact with Danielle Peyton at the firm for more details regarding participation in the investigation. As many investors seek damages for potential negative impacts on their investments, staying informed is paramount.

The Future for Investors

As the investigation progresses, potential class action lawsuits may emerge if wrongdoing is established. Investors are encouraged to remain vigilant about any communications from Aquestive, as transparency from the company will be essential moving forward. Given the current decline in stock value, investors face heightened uncertainty about their financial stakes in the company.

To keep abreast of developments, it's advisable for investors to monitor updates regularly from both Pomerantz LLP and Aquestive Therapeutics. Any legal changes or court outcomes could influence the company’s market standing and contribute to potential recoveries for investors.

As we move forward, the importance of legal representation in matters of corporate securities cannot be understated—especially in light of this alarming investigation into the practices at Aquestive Therapeutics. Investors must not only protect their interests but also remain proactive in seeking justice for any potential grievances stemming from this situation.

For more details or inquiries about joining the class action, investors are reminded to reach out to the specified contacts at Pomerantz LLP.

This situation continues to develop, and staying informed will be invaluable for all stakeholders involved.